← Retour au Screener

Sector: Santé
Open in Terminal → EWTXLive chart · Key metrics · News · Smart money

Edgewise Therapeutics

EWTX Mid Cap

Healthcare · Biotechnology

Mis à jour: Aug 2, 2026, 22:14 UTC

33,32 €
-6.54% aujourd'hui
52W: 10,66 € – 41,96 €
52W Low: 10,66 € Position: 72.4% 52W High: 41,96 €

Price Chart

Indicateurs clés

P/E Ratio
Cours/Bénéfice
Forward P/E
P/E prévisionnel
P/S Ratio
Cours/Ventes
EV/EBITDA
Valeur d'entreprise/EBITDA
Rend. dividende
Rendement annuel du dividende
Cap. boursière
3,6 Md €
Capitalisation boursière
Croissance du CA
Croissance du CA sur un an
Marge bénéficiaire
Marge nette
ROE
-38.14%
Rentabilité des capitaux propres
Beta
0.28
Sensibilité au marché
Positions vendeuses
13.25%
% du flottant vendu à découvert
Volume moyen
1,426,537
Volume quotidien moyen

Valuation Analysis

Signal
N/A
vs. S&P 500 avg P/E (24.7x)
Analyst Consensus
None
13 analysts
Avg. Price Target
43,28 €
+29.91% upside
Target Range
26,01 € – 57,22 €

About the Company

Sector: Healthcare Industry: Biotechnology Country: United States Employees: 154 Exchange: NMS

Edgewise Therapeutics en bref

Edgewise Therapeutics (EWTX) is currently trading at 33,32 € with a market capitalization of 3,6 Md €. The 52-week range spans from 10,66 € to 41,96 €; the current price is 20.6% below the yearly high.

💰 Dividende

Edgewise Therapeutics currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

13 analystes évaluent Edgewise Therapeutics (EWTX) au consensus : None. L'objectif de cours moyen est de 43,28 €, soit un potentiel de +29.91% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 26,01 € à 57,22 €.

Edgewise Therapeutics : la thèse d'investissement en détail

Edgewise Therapeutics (EWTX) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario baissier

Short interest sits at 13.25% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

À surveiller

  • The analyst consensus price target implies 29.91% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Points forts
  • Bilan solide avec faible endettement (D/E 0.77)
Points faibles
  • Positions vendeuses élevées (13.25%)
  • Free cash flow négatif

Aperçu technique

MM 50 jours
33,17 €
+0.44% vs. cours
MM 200 jours
25,77 €
+29.31% vs. cours
Sous le plus haut 52s
−20.6%
41,96 €
Au-dessus du plus bas 52s
+212.4%
10,66 €

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Profil de risque

Risque de marché (Bêta)
0.28 · Défensive
Évolue moins que le marché global
Positions vendeuses
13.25% · Élevé
% du flottant vendu à découvert
Dette/Capitaux propres
0.77 · Faible
Dette totale / capitaux propres

The data points to relatively defensive market behavior, elevated short interest (13.25%).

Trading Data

50-Day MA: 33,17 €
200-Day MA: 25,77 €
Volume: 1,150,208
Avg. Volume: 1,426,537
Short Ratio: 6.06
P/B Ratio: 8.37x
Debt/Equity: 0.77x
Free Cash Flow: -78 476 901 €

More Santé stocks

Top peers in the same sector — ranked by market cap.

View full Santé sector page →

Where can I buy Edgewise Therapeutics?

Compare top-rated brokers — low fees, trusted providers, fully regulated.

📊 Plutôt un fonds qu’une action isolée ? Comparatif d’ETF :

Live Market Data

Real-time chart, financials, earnings, analysts, insider trades, events & news

Financials

Earnings

Analyst Ratings

Insider Trades

Events Timeline

News + Sentiment

Peer Comparison

Retour en haut